NASDAQ:HILS Hillstream BioPharma (HILS) Stock Price, News & Analysis → Jeff Bezos & 48 Members of Congress Are Buying ONE Sector… (From InvestorPlace) (Ad) Free HILS Stock Alerts $3.35 +0.01 (+0.30%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$3.21▼$3.6650-Day Range$0.23▼$5.2052-Week Range$0.19▼$2.65Volume120,376 shsAverage Volume1.39 million shsMarket Capitalization$58.97 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrends Get Hillstream BioPharma alerts: Email Address Ad The Freeport SocietyA Silent Invasion of AmericaThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern border is a travesty, but the 'invasion' I've found will have 10 times greater effects on our economy, and ultimately our way of life.Go here to see why. About Hillstream BioPharma Stock (NASDAQ:HILS)Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.Read More HILS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HILS Stock News HeadlinesApril 17, 2024 | morningstar.comHill & Smith PLC HILSOctober 31, 2023 | morningstar.comKiromic BioPharma Inc Ordinary Shares KRBPSeptember 22, 2023 | finance.yahoo.comHillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.September 21, 2023 | finance.yahoo.comDawson James Securities Announces October Date for 8th Annual Small Cap Growth ConferenceSeptember 11, 2023 | finance.yahoo.comHillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic PruritisSeptember 8, 2023 | finance.yahoo.comHillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13August 30, 2023 | benzinga.comHillstream – Drug Maker Licenses Critical New Technology In Fight Against CancerAugust 25, 2023 | seekingalpha.comNMTRQ 9 Meters Biopharma, Inc.August 9, 2023 | finance.yahoo.comHillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023July 20, 2023 | finance.yahoo.comHillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215July 10, 2023 | finance.yahoo.comHillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and BiologicsJuly 6, 2023 | finance.yahoo.comHillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian CancersJune 9, 2023 | finance.yahoo.comHILS - Hillstream BioPharma, Inc.May 15, 2023 | finance.yahoo.comHillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly AndersonMay 4, 2023 | finanznachrichten.deHillstream BioPharma, Inc.: Hillstream BioPharma Announces Closing of Public Offering of Common StockMay 2, 2023 | finance.yahoo.comHillstream BioPharma Announces Closing of Public Offering of Common StockMay 2, 2023 | finance.yahoo.comHillstream BioPharma to Present at Upcoming May 2023 Investor and Industry ConferencesApril 29, 2023 | benzinga.comHillstream BioPharma Stock (NASDAQ:HILS), Short Interest ReportApril 28, 2023 | finanznachrichten.deHillstream BioPharma, Inc.: Hillstream BioPharma Announces Proposed Public OfferingApril 28, 2023 | marketwatch.comHillstream BioPharma Shares Slide Premarket on Stock Offering >HILSApril 28, 2023 | investorplace.comWhy Is Hillstream BioPharma (HILS) Stock Down 57% Today?April 28, 2023 | finanznachrichten.deHillstream BioPharma, Inc.: Hillstream BioPharma Announces Pricing of Public OfferingApril 27, 2023 | finance.yahoo.comHillstream BioPharma Announces Pricing of Public OfferingApril 27, 2023 | finance.yahoo.comHillstream BioPharma Announces Proposed Public OfferingApril 13, 2023 | tmcnet.comHillstream BioPharma Selects OncoBay Clinical to Advance ClinicalSee More Headlines Receive HILS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hillstream BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HILS CUSIPN/A CIK1861657 Webwww.hillstreambio.com Phone908-955-3140FaxN/AEmployees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,470,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-188.44% Return on Assets-149.61% Debt Debt-to-Equity RatioN/A Current Ratio3.01 Quick Ratio3.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book6.98Miscellaneous Outstanding Shares17,603,000Free Float12,280,000Market Cap$58.97 million OptionableNot Optionable Beta3.08 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Randy D. Milby MBA (Age 69)Pres, Chairman & CEO Comp: $471.94kMr. Sireesh Appajosyula Pharm.D. (Age 47)COO & Director Comp: $64.96kMr. Thomas P. Hess CPA (Age 59)MBA, Chief Financial Officer Key CompetitorsQ32 BioNASDAQ:QTTBImmutepNASDAQ:IMMPAkebia TherapeuticsNASDAQ:AKBANektar TherapeuticsNASDAQ:NKTRPyxis OncologyNASDAQ:PYXSView All Competitors HILS Stock Analysis - Frequently Asked Questions Should I buy or sell Hillstream BioPharma stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hillstream BioPharma in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HILS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HILS, but not buy additional shares or sell existing shares. View HILS analyst ratings or view top-rated stocks. How have HILS shares performed in 2024? Hillstream BioPharma's stock was trading at $0.2305 on January 1st, 2024. Since then, HILS shares have increased by 1,353.4% and is now trading at $3.35. View the best growth stocks for 2024 here. When did Hillstream BioPharma IPO? Hillstream BioPharma (HILS) raised $21 million in an IPO on Wednesday, January 12th 2022. The company issued 3,750,000 shares at a price of $5.00-$6.00 per share. How do I buy shares of Hillstream BioPharma? Shares of HILS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HILS) was last updated on 6/16/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredA Silent Invasion of AmericaThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hillstream BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hillstream BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.